KEYTRUDA® (pembrolizumab) KEYNOTE-048 5-year data

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF, 1.20 MB

Download the interactive PDF to learn about the 5-year exploratory long-term follow-up data from KEYNOTE-048.1

KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.2

KEYTRUDA is associated with immune-related adverse events, please refer to the Summary of Product Characteristics before prescribing.

More information about KEYTRUDA® (pembrolizumab) in first-line head and neck squamous cell carcinoma:

Register with MSD Connect

Sign up for events
Access learning modules
Receive cancer resources
Access additional content

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website


  1. Tahara M et al. Presented at ESMO 2022. September 9–13, 2022. Abstract 659MO.
  2. KEYTRUDA Summary of Product Characteristics.